Acquisition balances victory portfolio.
SAN DIEGO -- Victory Pharma, Inc. has completed its acquisition of almost all of the assets of MiddleBrook Pharmaceuticals Inc.
The addition of MiddleBrook's product portfolio expands Victory's offerings to include the anti-infective drugs Moxtag and Keflex as well as the Pulsys drug delivery technology platform.
"This acquisition reflects our strategy of leveraging our existing commercial infrastructure to expand our portfolio of marketed products," Victory president and chief executive officer Matt Heck says.
"The addition of these products balances our portfolio nicely," he says, explaining that Victory's main drug, the antiarthritis medication Naprelan, is used mostly in the spring and summer, while Moxtag sales peak during the flu season.
Heck says Victory's history of marketing anti-infective drugs should drive sales of Moxtag.
The drug, which is the only once-daily formulation of amoxicillin that has received Food and Drug Administration approval, is indicated for the treatment of tonsillitis and/or pharyngitis.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Branded Drugs; Victory Pharma, Inc. acquired MiddleBrook Pharmaceuticals Inc.|
|Publication:||Chain Drug Review|
|Article Type:||Brief article|
|Date:||Aug 30, 2010|
|Previous Article:||Panel says Avandia should stay.|
|Next Article:||Progress made in war on diabetes.|